




RSV IASSIST QUICK REFERENCE GUIDE

Getting started

1 Go to the iAssist portal at <https://hcp.iassist.com/login>

- If you're a new user, create an account
- If you're an existing user, log in with your email and password

2 Your iAssist dashboard—menus and functions



Utility navigation menu—account and profile functions

- **My practice**—Register practice locations, prescribers, and office staff
- **Profile**—Create your iAssist profile with key information and preferences
- **Help**—Email the iAssist Help Guide with any operating questions
- **Log out**—Log out from your account

Top navigation menu—key functions

- **Dashboard**—Homepage, access to your main menus
- **Messages**—Receive messages related to prescriptions
- **Patient**—View logged patients for general information or preparing a submission
- **Reports**—At-a-glance information on patients, prescriptions, drafts, and messages

Bottom menu—quick links

- **Saved drafts**—Submission drafts in progress
- **Recent submissions**—Recent submissions
- **Recently created patients**—Recently created patients
- **Notifications**—Notifications regarding any patient or submission
- **Shortcut to the reports menu**—Shortcuts to your reports

Submission menu—prepare a submission

3 Need technical assistance?

- Contact the Help Desk (information on every page)

877-450-4412

877-432-4412

Email using the link

For immediate assistance, click "Live Chat" at the bottom of each page



Patient information and functions

1 View all logged patients in the “Patients” top navigation menu


- Choose a patient from the list or use the search function to find a patient

Patient information menu

- **Overview**—Patient and practice information
- **Patient log**—Diagnosis information, appointments and doses, clinical notes
- **Insurance**—Primary and secondary insurance
- **History**—Submission history through iAssist
- **Documents**—Patient documents uploaded during workflow

2 Perform functions for patients logged into the system

- Prepare a submission
- Manage information, like appointments and doses



Overview of submissions

1 Perform 2 types of submissions

- Prescription
- Prior authorization/re-authorization form

2 Begin a submission in 1 of 2 ways:

- For a patient who hasn't been inputted into the system:
 - Click the “Patients” tab then “Add new patient” (Located in menu on the left)
 - Input initial patient information then choose submission type
- If the patient already exists in the system:
 - Begin the submission right from the dashboard by clicking “start now”
 - Search for and select patient then choose submission type

3 Before starting a submission, it is recommended that you have key information available

- SYNAGIS® (palivizumab) patient log
- Medical information
- Insurance and pharmacy card information
- Discharge summary
- NICU notes
- Any other documentation you would typically submit

Please see **Important Safety Information on page 4, and accompanying full Prescribing Information for SYNAGIS, including Patient Information.**



Completing each submission type

For each submission, be sure to input all pertinent information and upload all necessary documents

- *Note: On any page, you can save the submission as draft, and when you are ready, resume the submission from the dashboard*

1 ePrescription

- Step 1: Patient prescription
- Step 2: Patient authorization
- Step 3: Patient information
- Step 4: Pharmacy selection
- Step 5: Medical history
- Step 6: Review
- Step 7: Confirmation

2 Prior authorization/re-authorization form

- Step 1: Patient prescription
- Step 2: Patient authorization
- Step 3: Patient information
- Step 4: Prior authorization
- Step 5: Review
- Step 6: Confirmation

After each submission, you'll have the option to:



Download/preview SPP form



Print confirmation



Return to the dashboard



IMPORTANT SAFETY INFORMATION

- SYNAGIS is contraindicated in children who have had a previous significant hypersensitivity reaction to SYNAGIS
- Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to SYNAGIS. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to SYNAGIS. The relationship between these reactions and the development of antibodies to SYNAGIS is unknown. If a significant hypersensitivity reaction occurs with SYNAGIS, its use should be permanently discontinued. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration of SYNAGIS
- As with any intramuscular injection, SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder
- Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays
- Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported

INDICATION

SYNAGIS is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

- with a history of premature birth (≤ 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
- with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
- with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

LIMITATIONS OF USE

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

DOSING

The recommended dose of SYNAGIS is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of SYNAGIS should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.

The efficacy of SYNAGIS at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

Please see Important Safety Information above and accompanying full Prescribing Information for SYNAGIS, including Patient Information.

